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Background
The past three decades of studies have unveiled some of 
the genetic underpinnings of human disease. For complex 
diseases,  those  with  obscure  genetic  roots,  discoveries 
have accelerated recently owing to a bloom of genome-
wide association studies (GWASs) [1]. Nevertheless, even 
for the most successful cases (such as inflammatory and 
ulcerative  bowel  disease  [2,3]),  discoveries  account  for 
only a fraction, often small, of the disease’s heritability. 
These yet to be discovered genetic variants comprise the 
‘missing  heritability’  or  the  genetic  ‘dark  matter’  for 
disease.
State of dark matter
Heritability, the proportion of trait variability explained 
by genetic factors, has two somewhat different meanings. 
Narrow-sense  heritability  involves  only  the  additive 
effects  of  genes.  Broad-sense  heritability  involves  both 
additive and non-additive effects. The difference between 
the two makes a difference when hunting for dark matter. 
If  genetic  variation  were  all  to  act  additively,  the  best 
predictor  of  an  offspring’s  trait  value  would  be  the 
average of his/her parents’ values. Human height is an 
excellent example, after adjusting for gender. Hunting for 
dark matter for a trait such as human height will be more 
straightforward than for a disease such as schizophrenia, 
for which the evidence for substantial gene-gene inter-
action is compelling [4]. Yet when researchers refer to 
heritability  of  human  height,  they  implicitly  mean 
narrow-sense  heritability;  for  schizophrenia,  it  is 
heritability in a much broader sense.
Why should we care about the genetic basis of disease? 
Greater  understanding  of  the  genetics  equals  greater 
understanding  of  molecular  etiology  and,  with  it, 
eventually more cogent treatments. However, the origins 
of some human diseases, especially those of the mind, 
can be mysterious. For diseases of the mind, few environ-
mental or genetic risk factors are understood; instead the 
hope is that identified genetic factors will lead to a subtler 
understanding  of  why  diseases  such  as  schizophrenia 
arise and how they can be treated effectively. Even for 
cardiovascular  disease,  for  which  environmental  risk 
factors  are  well  characterized,  new  insights  into  its 
genetics  could  produce  more  targeted  treatment.  This 
leads  to  the  other  expectation  -  that  greater  genetic 
knowledge will pave the way for ‘personalized’ medicine. 
The rapid technological advances in genomics will soon 
make it feasible to sequence whole genomes at relatively 
low  cost.  The  idea  that  each  individual  will  have 
meaningful sequence variation in their medical records 
and will have interventions tailored to their risk profile 
and likely treatment response is quite appealing. The goal 
of personalized medicine, however, is hindered because 
so much molecular etiology remains in the dark.
One  way  to  explain  more  of  the  dark  matter  is  to 
develop  more  efficient  ways  to  use  existing  data. 
Naukkarinen et al. [5] develop an innovative approach 
that integrates gene expression and genotype data. They 
apply these ideas to a GWAS of obesity, as measured by 
body  mass  index  (BMI).  Studies  estimate  BMI’s 
heritability at 45 to 85%, but identified genetic variants 
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more variants, the authors [5] examined gene expression 
of adipose tissue in a sample of monozygotic (MZ) twins 
discordant  for  BMI  and  in  a  sample  of  unrelated 
individuals. Because MZ twins are genetically identical, 
or  nearly  so,  the  authors  reasoned  that  genes  showing 
expression differences between twins are ‘reactive’ genes 
with differences that are due to regulatory or epigenetic 
changes  in  response  to  environmental  factors.  By 
contrast, genes uncovered in unrelated individuals are a 
combination of reactive and genetically ‘causal’ genes. By 
contrasting  results  from  the  unrelated  sample  and 
discordant  MZ  twins,  the  authors  identified  27  causal 
genes that were differentially regulated. They then tested 
197  single  nucleotide  polymorphisms  (SNPs)  falling  in 
and around these genes in a sample of 21,000 subjects. 
They discovered a significant excess of small P-values in 
this  set  of  SNPs.  Neither  the  set  of  SNPs  defined  by 
reactive genes nor the individual SNPs in the reactive set 
were associated with BMI. Notably, this work identifies a 
new gene, F13A1, which encodes the coagulation factor 
XIII A chain, with variation that affects BMI. This gene 
has also been identified by meta-analysis of 12 studies of 
venous thromboembolism [7]. Obesity is well known to 
predispose  to  vein  thromboses;  however,  the  study  of 
Naukkarinen et al. [5] reveals a potential biological path-
way for the relationship between obesity, thrombosis and 
cardiovascular risk.
The methods advanced by Naukkarinen and colleagues 
[5] require discordant MZ twins, which were available for 
BMI. This experimental design could prove highly infor-
ma  tive for similar quantitative traits, for which extremes 
are  easily  identified  and  by  which  the  pathology  or 
phenotype  of  interest  is  defined.  For  some  diseases, 
especially  diseases  of  the  brain,  quantitative  traits  that 
map precisely onto risk are not yet available. In addition, 
because  reactive  genes  are  environment-dependent, 
successful implementation of this design might require a 
sample exposed to a homogeneous environment, limiting 
its  generality.  Regardless,  this  study  shows  how  inno-
vative  research  can  cast  more  light  on  dark  matter. 
Moreover, the study design could also inform us about 
pathways of correlated gene expression and how much 
these  correlations  are  influenced  by  genetic  and 
environmental variation.
Many  other  methods  and  designs  are  available  to 
illuminate dark matter [8-15]. One appealing approach 
teams  gene-expression  results  with  genome-wide  asso-
cia  tion data to produce targeted hypothesis tests [8]. One 
possibility is to organize tests by expression quantitative 
trait loci affecting genes in pathways meaningful for the 
disease.  Statistical  methods  for  targeted  testing  are 
available, whether on the basis of prior information of the 
likelihood  of  an  association  between  a  SNP  and  the 
phenotype or on the basis of plausible disease pathways 
[9,10]. Genetic variants with parental origin effects, or 
whose  effects  depend  on  the  parent  from  whom  they 
were inherited, could be part of the dark matter; methods 
are  now  available  to  determine  the  parental  origin  of 
alleles and haplotypes even in the absence of genotyped 
parents [13]. Studies of copy number variants and their 
inheritance  in  families  could  also  reveal  insight  into 
plausible biological pathways for disease [14,15]. It is also 
safe to say that rare variants account for some of the dark 
matter  [16],  possibly  the  majority  of  it  in  some  cases. 
Next-generation sequencing promises to fill some of our 
void  in  knowledge  by  identifying  more  penetrant  but 
rarer variants.
Other approaches are less illuminating. Let’s reconsider 
human  height.  We  know  numerous  rare  variants  and 
about 50 common variants that have an impact on height. 
Thus far, known genetics account for roughly 5% of the 
variance. Using many SNPs from GWAS analysis that are 
not significantly associated with height, Yang et al. [17] 
estimated the proportion of variance in height explained 
by  SNPs  as  0.45  and  even  got  close  to  the  heritability 
estimate of 0.84 after correcting for incomplete linkage 
disequilibrium  between  SNPs  genotyped  and  causal 
variants.  In  spirit,  this  approach  [17]  is  similar  to  the 
allele score method [18], which seeks a predictive model 
for disease status on the basis of thousands of SNPs with 
modest  evidence  for  association.  If  their  results  are 
correct, both studies [17,18] suggest that the effects of 
SNPs  are  small  and  will  be  difficult  or  impossible  to 
detect  from  simple  analyses  of  GWASs,  at  least  for 
current  sample  sizes  [19].  These  intriguing  approaches 
have  some  drawbacks:  they  shed  no  new  light  on  the 
molecular  etiology  of  phenotype;  and  inherent  in  the 
calculations are assumptions that could prove difficult to 
validate.
We all recognize the hidden biases that inflate estimates 
of heritability. There are other complex pathways for the 
transmission of a phenotype across generations without 
the transmission of a specific common or rare variant, 
namely through epigenetic factors that can result in the 
inheritance  of  gene  expression  patterns  without  an 
alteration of the DNA sequence [20]. Gene-environment 
interactions could also affect the estimates of heritability 
and when they are in play, they can explain as much of 
the variance in the phenotype as genetic factors [21].
Conclusions
Concerted effort will almost surely be required to under-
stand the genetic architecture of most complex diseases. 
Naukkarinen et al.’s [5] novel study design illustrates the 
impact that concerted effort can have in advancing our 
knowledge of the genetic etiology of such diseases. There 
remains  ample  room  for  novel  analytic  methods  and 
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disease. It is entirely possible, 10 years hence, that we will 
realize that much of the missing heritability was hiding in 
plain sight in common variants.
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